University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 12 of 16
Laser Based Focal Ablation of Low Grade Prostate Cancer
NCT01192438
Understanding Sleep in Hospitalized Older Patients
NCT01057823
Development and Validation of a Tool to Measure Hand-off Quality
NCT01059942
A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients
NCT01183494
Effect of Omega-3 Supplementation During Pregnancy on Regulation of Stress
NCT01158976
Investigation of Genetic Determinants of Capecitabine Toxicity
NCT00977119
Effects of Continuous Positive Airway Pressure (CPAP) Treatment on Glucose Control in Patients With Type 2 Diabetes
NCT01136785
Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer
NCT01011946
Intraoperative Bleeding During Endoscopic Sinus Surgery
NCT01014728
Vitamin D for Chronic Sinusitis
NCT01007799
Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms
NCT01007253
Effect of Prednisone onTregs and TH17
NCT01002313
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer
NCT01012440
Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk
NCT01156116
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
NCT01206426
Investigation of Cisplatin-Related Kidney Toxicity
NCT00984035
N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
NCT00967005
Ultrasound Determination of Needle Depth in Epidurals in Adult Patients
NCT00981916
Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)
NCT01059929
Clinical and Economic Implications of Genetic Testing for Warfarin Management
NCT00964353
Cardiometabolic Risk of Shiftwork
NCT01264913
Teaching Use of Respiratory Inhalers (TURI)
NCT01456494
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
NCT01706432
Tolcapone Treatment of Pathological Gambling
NCT00927563
Safety and Efficacy of Computer Assisted Surgery for Use in Vascular Surgery Procedures
NCT01136811
Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: Vacuum Assisted Closure (VAC) and Gauze Suction (GSUC)
NCT00952120
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
NCT01342354
Stress Testing and Cardiac Magnetic Resonance
NCT00871260
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
NCT00870220
The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)
NCT00887315
Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
NCT00857792
Memantine in the Treatment of Kleptomania
NCT00880685
Cardiovascular Complications of Sickle Cell Disease
NCT01044901
Individual Differences in Diabetes Risk: Role of Sleep Disturbances
NCT00989976
Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls
NCT00829972
Improving Diabetes Care and Outcomes on the South Side of Chicago
NCT01087073
MRSA Colonization and Control in the Dallas County Jail
NCT00785200
Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children
NCT01938014
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
NCT00829296
Continuous Venovenous Hemofiltration Versus Continuous Venovenuous Hemodialysis
NCT01062984
Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)
NCT00840294
Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women
NCT00786409
Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen
NCT00791973
Susceptibility to Pathological Gambling
NCT01528982
Individual Differences in Diabetes Risk: Role of Slow WaveSleep
NCT00989378
Sleep Disturbances as a Risk Factor in Chronic Kidney Disease
NCT00817427
Primary Care Patients With Depression for Internet-Based Social Support
NCT00886730
Celiac Disease Database
NCT01172665
ACT-HF: Attention, Cognition and Self-Management in Heart Failure
NCT01064765
Naltrexone in the Treatment of Trichotillomania
NCT00775229
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.